FDA Approvals, Label Expansions & Key Regulatory Milestones
GLP-1 receptor agonists did not arrive fully formed as the blockbuster drug class they are today. They emerged from decades of incremental scientific progress. Theyn were built approval by approval through a regulatory process that progressively expanded. What started as a modestly useful injectable for Type 2 diabetes management has evolved — through multiple generations of drug development and regulatory review — into a therapeutic platform being studied and approved across obesity, cardiovascular disease, kidney disease, sleep apnea, and a growing list of other conditions.
This timeline documents FDA approvals, major label expansions, as well as regulatory milestones. These events have defined the GLP-1 drug class from its first approval in 2005 through today, together with a forward-looking assessment of next-generation therapies in the pipeline. For patients, clinicians, and legal professionals following GLP-1 litigation, this regulatory history provides essential context. Stakeholders and researchers can understand when a drug was approved, for what indication, and under what labeling conditions. This analysis is fundamental to evaluating liability timelines and the adequacy of manufacturer disclosures at any given point in the class’s development.
Phase 1: The First GLP-1 Drug Era (2005–2010)
The first GLP-1 receptor agonist reached patients in 2005, more than a decade after researchers had identified glucagon-like peptide-1 as a promising therapeutic target. The early drugs in this class established the pharmacological principle but were limited by inconvenient dosing schedules and a narrow approved indication. The period from 2005 to 2010 was foundational — proving the mechanism worked clinically while laying the groundwork for the expanded approvals that followed.
2005 — First GLP-1 Drug Approved — Exenatide (Byetta)
The FDA approved exenatide — marketed as Byetta by Amylin Pharmaceuticals and Eli Lilly — as the first GLP-1 receptor agonist cleared for clinical use in patients with Type 2 diabetes mellitus. The drug required twice-daily subcutaneous injections, a dosing burden that limited its appeal, but its approval established the GLP-1 class as a viable and novel therapeutic category. Byetta demonstrated that pharmacologically amplifying the body’s natural incretin response could meaningfully improve glycemic control, and it set the template for the more refined agents that followed.
The clinical significance of the 2005 approval extended beyond Byetta itself. It validated the GLP-1 receptor as a druggable target for metabolic disease and sparked a wave of investment in longer-acting, more potent GLP-1 compounds across the pharmaceutical industry.
2010 — Liraglutide (Victoza) Approved
The FDA approved liraglutide — marketed as Victoza by Novo Nordisk — for the treatment of Type 2 diabetes. Unlike exenatide, which required twice-daily dosing, Victoza was administered as a once-daily injection — a meaningful improvement in patient convenience that contributed to its rapid adoption. Victoza became one of the leading GLP-1 therapies globally during this period and established Novo Nordisk as the dominant player in the class, a position the company has maintained and expanded through successive semaglutide-based products.
Phase 2: Expansion and Long-Acting Formulations (2011–2017)
The second phase of GLP-1 drug development was defined by two parallel advances: the move toward longer-acting, once-weekly formulations that dramatically improved adherence, and the first expansion of the drug class beyond diabetes into obesity treatment. By the end of this phase, GLP-1 drugs had begun the transition from a specialized diabetes medication into a broader cardiometabolic therapeutic class with growing clinical applications.
2012 — Extended-Release Exenatide (Bydureon) Approved
The FDA approved once-weekly exenatide extended-release, marketed as Bydureon — the first long-acting GLP-1 drug to reach patients. The shift from twice-daily to once-weekly dosing addressed one of the primary patient adherence challenges with earlier formulations and demonstrated that sustained GLP-1 receptor engagement could be achieved with a single weekly injection. Bydureon set a new standard for dosing convenience that subsequent drugs in the class would build upon.
2014 — Dulaglutide (Trulicity) Approved
Eli Lilly received FDA approval for dulaglutide — marketed as Trulicity — for Type 2 diabetes, administered as a once-weekly injection. Trulicity incorporated a simplified, single-use auto-injector that reduced administration complexity and improved patient experience compared to earlier formulations. It rapidly became one of the most prescribed GLP-1 drugs in the United States and remains a significant product within the current GLP-1 litigation. Also approved in 2014, though later discontinued for commercial rather than safety reasons, was albiglutide (Tanzeum).
2014–2015 — First Obesity Approval — Liraglutide (Saxenda)
The FDA approved liraglutide at a higher dose — marketed as Saxenda, also by Novo Nordisk — for chronic weight management in adults with obesity or overweight with at least one weight-related condition. This was a landmark regulatory moment for the class: GLP-1 drugs had crossed from diabetes management into the substantially larger and historically underserved market for pharmacologic obesity treatment. Saxenda was the first GLP-1 drug approved specifically for weight loss, and it laid the commercial and regulatory groundwork for Wegovy’s later arrival.
Saxenda is also a significant drug from a litigation perspective, as it appears alongside semaglutide and tirzepatide products in the current GLP-1 MDL proceedings. Patients who were prescribed Saxenda for weight management and developed gastroparesis, bowel obstruction, pancreatitis, or gallbladder disease are among the plaintiffs pursuing claims.
Phase 3: Cardiovascular Outcomes and the Semaglutide Era (2016–2020)
The third phase of GLP-1 regulatory history was shaped by two developments of lasting significance. First, the publication and regulatory recognition of cardiovascular outcomes trial data established that GLP-1 drugs could reduce the risk of major adverse cardiovascular events in high-risk patients — shifting the class from a glycemic management tool to a cardiometabolic therapy. Second, the arrival of semaglutide introduced a substantially more potent agent that would come to dominate the class and define the modern GLP-1 era.
2016 — Cardiovascular Benefit Recognized — Liraglutide (Victoza)
Based on the LEADER cardiovascular outcomes trial, the FDA approved a label update for Victoza confirming its ability to reduce the risk of major adverse cardiovascular events — specifically heart attack, stroke, and cardiovascular death — in adults with Type 2 diabetes and established cardiovascular disease. This was the first time a GLP-1 drug had been approved for cardiovascular risk reduction, and it marked a fundamental shift in how the class was understood and prescribed. GLP-1 drugs were no longer simply glucose-lowering agents; they were emerging as comprehensive cardiometabolic therapies.
2017–2018 — Semaglutide (Ozempic) Approved
The FDA approved injectable semaglutide — marketed as Ozempic by Novo Nordisk — for the treatment of Type 2 diabetes. Administered as a once-weekly injection, Ozempic delivered substantially greater potency than earlier GLP-1 drugs, producing more pronounced reductions in HbA1c and body weight in clinical trials. It rapidly became the leading drug in the class and, within a few years, one of the most prescribed medications in the United States. The NDA for Ozempic is the regulatory foundation upon which the drug’s entire warning label history — and by extension much of the current litigation — rests.
2019 — First Oral GLP-1 Drug — Rybelsus Approved
The FDA approved oral semaglutide — marketed as Rybelsus by Novo Nordisk — for Type 2 diabetes, representing a major technological milestone for the class. Delivering a GLP-1 receptor agonist in oral tablet form required overcoming significant pharmaceutical challenges around absorption and bioavailability, as peptide molecules are typically degraded in the gastrointestinal tract before reaching systemic circulation. Rybelsus addressed this through a co-formulation with the absorption enhancer SNAC. As an oral product containing the same active ingredient as Ozempic and Wegovy, Rybelsus carries the same class-level safety concerns and is included in the current GLP-1 litigation.
Phase 4: The Obesity Revolution (2021–2023)
The fourth phase of GLP-1 regulatory history is, from a public health and commercial standpoint, the most consequential. A series of approvals between 2021 and 2023 established GLP-1 and dual-agonist drugs as the most effective pharmacologic weight-loss treatments ever approved, producing levels of weight reduction previously achievable only through bariatric surgery. This period also corresponds with the dramatic expansion in GLP-1 prescriptions — and the subsequent growth in adverse event reports — that gave rise to the current wave of litigation.
2021 — Wegovy Approved — Semaglutide for Obesity
The FDA approved semaglutide at a higher dose of 2.4 mg — marketed as Wegovy by Novo Nordisk — for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. The approval was based on the STEP clinical trial program, which demonstrated average weight reductions of approximately 15 percent — a level of efficacy that no previously approved pharmacologic weight-loss therapy had achieved. Wegovy’s approval transformed the obesity treatment landscape and triggered an unprecedented surge in patient demand for semaglutide-based medications.
Wegovy is one of the most frequently named drugs in the current GLP-1 litigation. Given its higher dose relative to Ozempic and the population for which it is indicated — patients with obesity who may not have diabetes — some researchers have noted that Wegovy users may face different or elevated risk profiles for certain adverse events, including NAION.
2022 — Tirzepatide (Mounjaro) Approved — A New Mechanism Enters
The FDA approved tirzepatide — marketed as Mounjaro by Eli Lilly — for the treatment of Type 2 diabetes. Tirzepatide is not a pure GLP-1 receptor agonist. It is a dual agonist that activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously, making it the first approved drug in a new subcategory of incretin-based therapies. Clinical trial data showed weight loss and glycemic control outcomes that surpassed earlier GLP-1 drugs, establishing tirzepatide as the new benchmark in the class.
Mounjaro and its obesity-indicated counterpart Zepbound are named alongside Ozempic and Wegovy in both MDL 3094 (gastrointestinal injury claims) and MDL 3163 (NAION vision loss claims). Eli Lilly faces the same failure-to-warn legal theories as Novo Nordisk, with tirzepatide’s more pronounced gastric-slowing mechanism being a central issue in the gastrointestinal injury litigation.
2023 — Zepbound Approved — Tirzepatide for Obesity
The FDA approved tirzepatide at higher doses under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Clinical data showed average weight reductions approaching and in some analyses exceeding 20 percent — setting a new benchmark for pharmacologic weight loss and approaching the outcomes historically associated with bariatric surgery. Zepbound’s approval in November 2023 completed Eli Lilly’s entry into the obesity drug market and intensified the commercial competition with Novo Nordisk’s semaglutide products.
2023 — Cardiovascular Indication Expanded for Wegovy
The FDA approved a label expansion for Wegovy confirming its ability to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This made Wegovy the first drug approved specifically for obesity that also carried an FDA-recognized cardiovascular risk reduction indication — a development that substantially broadened the prescribing rationale for the drug and contributed to further growth in the patient population being exposed to semaglutide.
Phase 5: Expansion Into New Disease Areas (2024–2026)
By 2024, the GLP-1 drug class had begun generating clinical trial data across a range of conditions well beyond its origins in diabetes and obesity management. The regulatory approvals and label expansions of this period reflect the breadth of therapeutic interest in GLP-1 and related incretin mechanisms — and signal the trajectory of approvals likely to unfold through the remainder of the decade.
2024 — Chronic Kidney Disease Indication — Semaglutide
Based on the FLOW trial, which demonstrated a significant reduction in kidney disease progression and kidney-related death in patients with Type 2 diabetes and chronic kidney disease, the FDA approved a new indication for semaglutide covering chronic kidney disease risk reduction. This approval extended semaglutide’s regulatory reach into a patient population — those with diabetic nephropathy — for whom treatment options had historically been limited, and it reinforced the drug’s positioning as a comprehensive cardiometabolic therapy rather than a glycemic management agent alone.
2024 — Sleep Apnea and Heart Failure Research Advances — Tirzepatide
Clinical trial data supporting tirzepatide’s utility in obstructive sleep apnea and heart failure with preserved ejection fraction (HFpEF) continued to mature, with regulatory pathways for these indications taking shape. The SURMOUNT-OSA trials demonstrated meaningful reductions in the severity of sleep apnea in tirzepatide-treated patients, generating significant interest from pulmonologists and sleep medicine specialists and moving the FDA review process forward on these expanded indications.
2025 — Oral GLP-1 Expansion and Pipeline Advances
Oral semaglutide accumulated additional cardiovascular outcomes data strengthening its position in the market, while next-generation oral GLP-1 candidates — most notably orforglipron, a small-molecule GLP-1 receptor agonist developed by Eli Lilly — advanced through late-stage clinical development. The emergence of oral small-molecule GLP-1 drugs represents a potential inflection point for the class: unlike peptide-based compounds, which require specialized formulation to survive gastrointestinal transit, small-molecule agonists can be administered as conventional tablets without absorption-enhancing technology.
Phase 6: Next-Generation Therapies (Expected 2026–2035)
The pipeline of next-generation incretin-based therapies is among the most active in pharmaceutical development. Several compounds in advanced clinical development are expected to reach FDA review over the coming years, with mechanisms and efficacy data that could again reset expectations for what pharmacologic weight loss and cardiometabolic therapy can achieve. The following are the most closely watched candidates and their anticipated regulatory trajectories.
Retatrutide — Triple Agonist (GLP-1 + GIP + Glucagon)
Retatrutide, in development at Eli Lilly, is a triple receptor agonist simultaneously targeting the GLP-1, GIP, and glucagon receptors. Phase 2 clinical data has shown weight loss outcomes approaching 24 percent at 48 weeks — levels comparable to some bariatric surgical procedures. The addition of glucagon receptor agonism is intended to drive thermogenesis and further enhance weight loss beyond what GLP-1 and GIP agonism alone can achieve. Regulatory approval is currently anticipated in the 2027 to 2029 timeframe pending the completion of Phase 3 trials.
CagriSema — Semaglutide + Amylin Analogue
CagriSema is a fixed-dose combination of semaglutide and cagrilintide, an amylin receptor agonist developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that contributes to satiety and gastric emptying regulation. The combination is designed to deliver enhanced weight loss through complementary mechanisms of action, with Phase 3 data expected to support a regulatory submission in the late 2020s. CagriSema represents Novo Nordisk’s attempt to maintain its competitive position in obesity pharmacotherapy as tirzepatide and retatrutide raise the efficacy bar.
Orforglipron — Oral Small-Molecule GLP-1 Agonist
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist in development at Eli Lilly. Because it is not a peptide, it does not require the specialized formulation approach used by Rybelsus and can be administered as a conventional once-daily tablet without dietary restrictions around dosing. Phase 3 data has demonstrated meaningful weight loss and glycemic benefits. Regulatory submission is anticipated in the 2026 to 2027 timeframe, and if approved, orforglipron would represent the first truly conventional oral GLP-1 drug — a development with significant implications for market access, patient adherence, and the competitive dynamics of the class.
Amycretin and VK2735
Several other pipeline candidates are attracting attention from clinical and investment communities. Amycretin — a combined GLP-1 and amylin receptor agonist in development at Novo Nordisk — is in earlier-stage clinical development but has shown promising early efficacy signals. VK2735, a dual GLP-1 and GIP agonist from Viking Therapeutics available in both injectable and oral formulations, is advancing through Phase 2 and Phase 3 trials with potential approval anticipated later in the decade.
Future Regulatory Trends: 2030 and Beyond
Looking further ahead, the regulatory trajectory of the GLP-1 class points toward continued expansion of both the delivery formats and the therapeutic indications for which these drugs are approved. Based on the clinical trial pipeline and emerging mechanistic research, the coming decade is expected to bring:
- Monthly or quarterly injectable formulations that further reduce dosing burden and improve long-term adherence
- Expanded oral options as small-molecule GLP-1 agonists and improved peptide formulation technologies mature
- Approvals in metabolic-associated steatohepatitis (MASH, formerly NASH), a liver disease for which GLP-1-based therapies have shown early promise
- Expanded cardiovascular, renal, and sleep apnea indications across multiple drugs in the class
- Research into potential applications in neurodegenerative conditions — including Alzheimer’s disease and Parkinson’s disease — where GLP-1 receptors expressed in the central nervous system may play a role
Key Regulatory Turning Points
Across two decades of approvals, a handful of regulatory moments reshaped not just the GLP-1 class but the broader landscape of metabolic medicine. The table below summarizes the milestones that had the most lasting impact on the class’s clinical trajectory and commercial development.
| Year | Milestone | Why It Mattered |
| 2005 | Byetta approved (first GLP-1 drug) | Proved the GLP-1 mechanism works clinically; established a new drug class |
| 2014–2015 | Saxenda approved (first obesity indication) | GLP-1 drugs move beyond diabetes into the vastly larger obesity market |
| 2016 | CV outcomes recognized — Victoza (LEADER trial) | GLP-1 drugs become cardiometabolic therapies, not just glucose-lowering agents |
| 2017–2018 | Ozempic approved (semaglutide) | More potent agent dominates the class; sets the stage for Wegovy and all current litigation |
| 2019 | Rybelsus approved (first oral GLP-1) | First non-injectable option; major technological milestone for the class |
| 2021 | Wegovy approved (~15% weight loss) | Modern pharmacologic obesity treatment era begins; unprecedented prescription growth |
| 2022–2023 | Mounjaro and Zepbound (tirzepatide dual agonist) | Multi-hormone therapy surpasses pure GLP-1; new efficacy benchmark for weight loss |
| 2024+ | CKD, sleep apnea, heart failure indications | Class expands well beyond diabetes and obesity into systemic cardiometabolic disease |
Why This Timeline Matters for GLP-1 Litigation
The FDA approval and label expansion history documented on this page is not merely regulatory housekeeping — it is directly relevant to the legal landscape surrounding GLP-1 drugs. For attorneys, plaintiffs, and anyone evaluating injury claims, the regulatory timeline performs several important functions.
First, it establishes the baseline against which warning adequacy is assessed. Each approval creates the initial label from which subsequent warning deficiencies are measured. A patient injured by a risk that was not disclosed on the label at the time of their injury has a foundational failure-to-warn argument regardless of what warnings were later added. Second, the timeline documents the expansion of the patient population being exposed to these drugs. The approvals of Wegovy in 2021 and Zepbound in 2023 brought millions of new patients — many without diabetes, prescribed off-label use, or with limited clinical oversight — into contact with drugs whose risk profiles were still being characterized. Third, the timeline illustrates the pace at which new indications have been added relative to the pace of safety signal detection and label updating. In pharmaceutical litigation, the gap between when a risk is known or knowable and when it appears on a drug’s label is where failure-to-warn liability is argued. Understanding the regulatory history in full provides the framework for evaluating those gaps.
The Relationship Between This Page and the Research Timeline
This approvals timeline documents what the FDA formally authorized and when. It is closely related to, but distinct from, the scientific research timeline that tracks the underlying clinical trials, mechanism studies, and post-market safety investigations that informed — or should have informed — regulatory decisions. The research timeline covers the clinical and scientific evidence base; this page covers the regulatory action taken on that evidence.
Together, the two timelines form an authority framework for understanding both the development of the GLP-1 class and the evidentiary basis for the current litigation. Discrepancies between what the research showed and when manufacturers acted on that research through label changes are among the most important issues in the pending MDL proceedings.